بدائل البحث:
largest decrease » larger decrease (توسيع البحث), marked decrease (توسيع البحث)
market decrease » marked decrease (توسيع البحث), marked increase (توسيع البحث), larger decrease (توسيع البحث)
web decrease » we decrease (توسيع البحث), teer decrease (توسيع البحث), step decrease (توسيع البحث)
a largest » _ largest (توسيع البحث), a large (توسيع البحث), a latest (توسيع البحث)
a market » _ market (توسيع البحث), a marker (توسيع البحث)
largest decrease » larger decrease (توسيع البحث), marked decrease (توسيع البحث)
market decrease » marked decrease (توسيع البحث), marked increase (توسيع البحث), larger decrease (توسيع البحث)
web decrease » we decrease (توسيع البحث), teer decrease (توسيع البحث), step decrease (توسيع البحث)
a largest » _ largest (توسيع البحث), a large (توسيع البحث), a latest (توسيع البحث)
a market » _ market (توسيع البحث), a marker (توسيع البحث)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
A summary of the included study characteristics.
منشور في 2025"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"
-
10
-
11
Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retr...
منشور في 2025"…This study evaluated the real-world impact of mepolizumab treatment in patients with severe asthma over a 4-year follow-up period.</p> <p>This was a retrospective cohort study of patients with asthma initiating mepolizumab (index date: first claim, November 2015–September 2019) using the Merative MarketScan Commercial and Medicare Databases. …"
-
12
-
13
-
14
-
15
-
16
List of Included studies.
منشور في 2025"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"
-
17
The search strategy in three databases.
منشور في 2025"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"
-
18
NIH score.
منشور في 2025"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"
-
19
List of excluded studies.
منشور في 2025"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"
-
20